Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced its financial results for full year 2008 and provided an overview of the development and pre-commercialization activities for naproxcinod, its lead investigational drug for the treatment of the signs and symptoms of osteoarthritis (OA).

Michele Garufi, Chief Executive Officer of NicOx, commented: "We believe NicOx has entered 2009 in its strongest strategic position to date. We intend to use the excellent platform that we have developed over the last several years to transform NicOx into a self-sustainable biopharmaceutical company. Central to our ambition is to maximize the strategic and economic value of naproxcinod by signing the most appropriate commercial deal for this unique new product. Our intention is to retain select commercialization rights to naproxcinod to enable the creation of our own sales and marketing operations. Therefore, in parallel with our on-going discussions with potential naproxcinod partners, we are accelerating our search for marketed or late-stage clinical products for in-licensing or acquisition to leverage our future commercial infrastructure. We are confident we will achieve these key near term milestones, which should position NicOx to deliver sustainable profitability in the mid-term."

    Key highlights 2008:

    - Successful completion of the phase 3 clinical program for naproxcinod
      in OA patients, with all three studies (301, 302 and 303) achieving
      highly statistically significant results on all three co-primary
      efficacy endpoints (the WOMAC(TM) pain and function subscales and
      patients' overall rating of disease status).

    - Positive results on naproxcinod's blood pressure profile from a
      prospectively designed statistical analysis of the pooled Office Blood
      Pressure Measurement (OBPM) data from the phase 3 pro
'/>"/>
SOURCE  NicOx
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bellingham, WA (PRWEB) May 24, 2013 ... researchers, engineers, and industry suppliers will present technologies ... life at the annual SPIE Optics and ... August. Organized by SPIE, the international society ... the largest international, multidisciplinary optical sciences and technology ...
(Date:5/24/2013)... Many factors impact tissues targeting such as protein ... the blood-tissue barrier. Even when tissue disposition is achieved, ... tissue rather than the total tissue concentration. , A ... guide lead optimization, predict in vivo activity in animal ... impact the likely human clinical dose. , In this ...
(Date:5/23/2013)... Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just praying that ... few doctors said he had a good chance of ... her now 20-month-old son, Kaiba. "At that point, we ... it and run with it." , They found hope ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Novelda AS announced today two new antennas for its CMOS ... based on a Sinuous Antenna geometry. The antenna itself consists of ... is the antenna itself; the lower PCB is a balancing network. ... This can be lowered by attaching a lens. This lens is ...
... WORCESTER, Mass. and TORONTO, Oct. 6, 2011 ... wholly-owned subsidiary Antigen Express, Inc. ( www.antigenexpress.com ), ... at the Second Annual "Cancer Immunotherapy: A Long-Awaited ... the New York Academy of Medicine in New ...
... isolated 63 unique dust particles from their laboratory and ... a new kind of sensor when dust got stuck inside ... of single dust particles. In a recent issue of ... how the discovery could aid the study respiratory diseases caused ...
Cached Biology Technology:Wideband Antenna for Novelda Nanoscale Impulse Radar 2Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 2Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 3Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 4Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 51 room -- 63 different dust particles? Researchers aim to build dust library 21 room -- 63 different dust particles? Researchers aim to build dust library 3
(Date:5/23/2013)... history museums of the world are billions of animal ... flowers, mushrooms and grasses, all stacked, stored and preserved ... diverse collections could be critical to understanding how the ... growing human footprint if only the information were ... life with the help of a team from the ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
(Date:5/22/2013)... cell powered buses, including a team from Simon ... processes and bus membrane durability. , The team ... in the operating cycle of the bus on ... study, led by SFU graduate student Natalia MaCauley, ... Burnaby-based Ballard Power Systems and funded by Automotive ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2
... Royal Society,s Geoengineering the Climate report, September,s Physics ... the need to start taking geoengineering deliberate interventions ... more seriously. Of increased ... binding carbon emission targets at December,s United Nation,s Convention ...
... Like most invasive plants introduced to the U.S. from ... to dominate the natives. A new study indicates that eventually, ... the soil becomes less potent. The study, in ... one of the first to show that evolutionary forces can ...
... U.S. Geological Survey has released the results of a ... reporting this month that glacial shrinkage is rapid and ... of Illinois geologist William Shilts spent nearly two decades ... 300 miles southwest of Thule, Greenland. He, his students ...
Cached Biology News:Time to lift the geoengineering taboo 2Over time, an invasive plant loses its toxic edge 2Over time, an invasive plant loses its toxic edge 3Shrinking Bylot Island glaciers tell story of climate change 2Shrinking Bylot Island glaciers tell story of climate change 3Shrinking Bylot Island glaciers tell story of climate change 4
... of the members of the GPCR family ... splicing--which has important implications for drug research. ... classical expression profiling and at the same ... of the gene that are expressed in ...
... ExonHit can design custom microarrays to detect ... list. Proprietary algorithms are used to ... from high quality, spliced cDNAs aligned to ... in a custom SpliceArray is profiled with ...
... Alternative Splicing plays an important role in ... apoptosis and cell death. Splice variants have ... and inhibition of defined apoptotic pathways. With ... can perform a classical expression profiling and ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Biology Products: